Source - LSE Regulatory
RNS Number : 0774Q
Oxford BioDynamics PLC
23 February 2021
 

23 February 2021

 

Oxford Biodynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

 

PUBLICATION OF 2020 ANNUAL REPORT

 

Oxford BioDynamics Plc (AIM: OBD), a biotechnology company developing precision medicine tests for personalized healthcare based on the EpiSwitch® 3D genomics platform, today announces that copies of its annual report and accounts for the year ended 30 September 2020 (incorporating the Notice of Annual General Meeting) ("Annual Report") have been posted to shareholders. An electronic copy of the Annual Report will be available on its website at investors.oxfordbiodynamics.com.

 

As stated in the recent Full Year results announcement, the Company's Annual General Meeting will be held at Oxford Works, Building 4650 Kingsgate, Oxford Business Park, Oxford, OX4 2SU on 24 March 2021 at 12.00pm.

 

-ENDS-

 

For further details please contact:

 

Oxford BioDynamics Plc

Tel: +44 (0)1865 518910

Jon Burrows, CEO

Paul Stockdale, CFO




Shore Capital - Nominated Adviser and Broker

Tel: +44 (0)20 7408 4090

Advisory: Edward Mansfield / John More

Broking: Fiona Conroy




Instinctif Partners

Tel: +44 (0)20 7457 2020

Melanie Toyne-Sewell / Agnes Stephens / Katie Duffell / Nathan Billis

OxfordBioDynamics@instinctif.com

 

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

The Company has developed a proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications.

Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma.

The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 10,000 samples in more than 30 human diseases. 

OBD is headquartered in Oxford, UK and is listed on the London Stock Exchange's AIM market. It also has a commercial team in the US and a reference laboratory in Penang, Malaysia.

For more information, please visit the Company's website, www.oxfordbiodynamics.com, or follow on Twitter or LinkedIn.

 

About EpiSwitch®

The 3D configuration of the genome plays a crucial role in gene regulation. By mapping this architecture and identifying abnormal configurations, EpiSwitch® can be used to diagnose patients or determine how individuals might respond to a disease or treatment.

Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics' award-winning, proprietary platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarkers. The technology is fully developed, based on testing of over 10,000 samples in 30 disease areas, and reduced to practice.

In addition to stratifying patients with respect to anticipated clinical outcome, EpiSwitch® data offer insights into systems biology and the physiological manifestation of disease that are beyond the scope of other molecular modalities. The technology has performed well in academic medical research settings and has been validated through its integration in biomarker discovery and clinical development with big pharma.

Oxford BioDynamics is leveraging its leading technology to develop a pipeline of tests in a wide range of indications, such as COVID-19 severity, immuno-oncology, neurodegenerative and autoimmune diseases.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACSFLFVVFLIVFIL
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.